FDA accepts Bristol-Myers Squibb’s application for lung cancer combo

Under Priority Review status, the FDA has accepted Bristol-Myers Squibb’s (NYSE:BMY) marketing application for Opdivo (nivolumab) + Yervoy (ipilimumab) for the first-line treatment of metastatic or recurrent non-small cell lung cancer with no EGFR or ALK mutations.

The agency’s action date is May 15.

https://seekingalpha.com/news/3531928-fda-accepts-bristol-myers-squibbs-application-for-lung-cancer-combo